Oct. 14 at 2:18 PM
Germany’s antitrust authority Bundeskartellamt has approved BioNTech’s acquisition of rival biotech firm CureVac, stating the deal does not threaten competition.
BioNTech announced in June its plan to acquire CureVac through an all-share offer valued at about
$1.25 billion (€1.08 billion) to strengthen its cancer immunotherapy portfolio.
During the pandemic, both companies researched COVID-19 vaccines, but only BioNTech successfully developed and commercialized one in partnership with Pfizer.
The regulator noted that BioNTech already markets the Comirnaty vaccine with Pfizer, while CureVac has no commercial products, and found no significant overlap in research activities. BioNTech is advancing several cancer immunotherapy projects, whereas CureVac’s candidates remain in early-stage trials.
$BNTX $PFE $CVAC